These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24654657)

  • 1. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.
    Saxena V; Manos MM; Yee HS; Catalli L; Wayne E; Murphy RC; Shvachko VA; Pauly MP; Chua J; Monto A; Terrault NA
    Aliment Pharmacol Ther; 2014 May; 39(10):1213-24. PubMed ID: 24654657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
    Bailly F; Virlogeux V; Dufour C; Pradat P; Hézode C; Larrey D; Alric L; Samuel D; Bourlière M; Métivier S; Zarski JP; Fontaine H; Loustaud-Ratti V; Serfaty L; Bronowicki JP; Carrat F; Zoulim F;
    Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):443-50. PubMed ID: 25636238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
    Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple therapy with boceprevir or telaprevir for prior HCV non-responders.
    Asselah T
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):455-62. PubMed ID: 23199504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.
    Sterling RK; Kuo A; Rustgi VK; Sulkowski MS; Stewart TG; Fenkel JM; El-Genaidi H; Mah'moud MA; Abraham GM; Stewart PW; Akushevich L; Nelson DR; Fried MW; Di Bisceglie AM
    Aliment Pharmacol Ther; 2015 Apr; 41(7):671-85. PubMed ID: 25627020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
    Miailhes P; Gilbert C; Lacombe K; Arends JE; Puoti M; Rockstroh JK; Sogni P; Fontaine H; Rosenthal E; Winnock M; Loko MA; Wittkop L; Dabis F; Salmon D;
    Liver Int; 2015 Sep; 35(9):2090-9. PubMed ID: 25650873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.
    Virlogeux V; Pradat P; Bailly F; Funingana G; Gonçalves F; Maynard M; Hartig-Lavie K; Amiri M; Zoulim F
    J Viral Hepat; 2014; 21(9):e98-e107. PubMed ID: 24612466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
    Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC
    J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients.
    Arends JE; van der Meer JT; Posthouwer D; Kortmann W; Brinkman K; van Assen S; Smit C; van der Valk M; van der Ende M; Schinkel J; Reiss P; Richter C; Hoepelman AI; ;
    Neth J Med; 2015 Aug; 73(7):324-30. PubMed ID: 26314715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
    Blázquez-Pérez A; San Miguel R; Mar J
    Pharmacoeconomics; 2013 Oct; 31(10):919-31. PubMed ID: 24000086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
    Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A; Serfaty L
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.
    Burton JR; O'Leary JG; Verna EC; Saxena V; Dodge JL; Stravitz RT; Levitsky J; Trotter JF; Everson GT; Brown RS; Terrault NA
    J Hepatol; 2014 Sep; 61(3):508-14. PubMed ID: 24801415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.
    Coppola N; Pisaturo M; Sagnelli C; Sagnelli E; Angelillo IF
    PLoS One; 2014; 9(4):e94542. PubMed ID: 24728219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].
    Giménez-Manzorro Á; García-González X; Rodríguez-González CG; Ochoa-Palominos A; Sanjurjo-Sáez M; Clemente-Ricote G
    Gastroenterol Hepatol; 2015 Dec; 38(10):575-82. PubMed ID: 26321320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
    Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC
    AIDS; 2015 Jan; 29(1):53-8. PubMed ID: 25387314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P; Reddy KR
    Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection.
    Wehmeyer MH; Eißing F; Jordan S; Röder C; Hennigs A; Degen O; Hüfner A; Hertling S; Schmiedel S; Sterneck M; van Lunzen J; Lohse AW; Schulze zur Wiesch J; Lüth S
    BMC Gastroenterol; 2014 May; 14():87. PubMed ID: 24884400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.